Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.
NCT ID: NCT05062421
Last Updated: 2021-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
540 participants
OBSERVATIONAL
2021-04-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The drugs to be administered to patients are:
* JAK-type kinase inhibitors.
* Monoclonal antibodies against TNF.
* Soluble receptor against TNF.
* Biosimilar FAMEb.
* Rituximab.
* Abatacept.
* Drugs that block IL6.
A follow-up will be carried out at 12, 24, 48, 60, 72 and 84 months from the start of treatment, to analyze how the patient's health improves.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cases 1
Patients treated with JAK-type kinase inhibitors.
No interventions assigned to this group
Cases 2
Patients treated with monoclonal antibodies against TNF.
No interventions assigned to this group
Cases 3
Patients treated with soluble receptor against TNF.
No interventions assigned to this group
Cases 4
Patients treated with FAME group biosimilars.
No interventions assigned to this group
Cases 5
Patients treated with rituximab.
No interventions assigned to this group
Cases 6
Patients treated with abatacept.
No interventions assigned to this group
Cases 7
Patients treated with drugs that block the IL6.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria.
* Who have received at least one of the doses of the study drugs.
* In follow-up in the consultations of the UGC of Rheumatology of the HUVM.
* With at least two complete evaluations (baseline and final) of clinical variables.
Exclusion Criteria
* Patients in whom more than 50% of the variables to be collected are missing in the data collection.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Blanca Estela Hernández Cruz
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario Virgen Macarena
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitario Virgen macarena
Seville, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Blanca Estela Hernández Cruz
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FIS-FME-2020-01
Identifier Type: -
Identifier Source: org_study_id